New group B strep guidelines clarify management of key groups

The CDC’s latest recommendations, endorsed by ACOG, spell out screening and intrapartum prophylaxis among women who experience preterm labor, preterm premature rupture of membranes, group B Streptococcus in urine, and allergy to penicillin

Janelle Yates, Senior Editor

Before widespread intrapartum prophylaxis against group B Streptococcus (GBS) was initiated in the late 1990s, roughly 7,500 newborns developed invasive GBS disease every year in the United States, and the case-fatality rate reached an astonishing—and disheartening—50%. Now that all pregnant women undergo culture-based screening at 35 to 37 weeks’ gestation, the incidence of early-onset neonatal GBS disease has declined precipitously.

According to a report issued late last year by the Centers for Disease Control and Prevention (CDC), GBS now causes roughly 1,200 cases of early-onset invasive disease every year, approximately 70% of them among infants born at or after 37 weeks’ gestation, and the case-fatality rate is 4% to 6%. Mortality is higher among preterm infants, with a case-fatality rate of 20% to 30% for infants born at or before 33 weeks’ gestation, compared with 2% to 3% for full-term infants.

Despite progress, GBS remains the leading cause of early-onset neonatal sepsis in the United States. In November 2010, to spur further improvement, the CDC updated its guidelines on prevention of perinatal GBS, and ACOG and other professional organizations endorsed the new recommendations. This article highlights changes to the guidelines—the first since 2002—in four critical areas:

- clarification of who should receive GBS prophylaxis, and when
- updated algorithms for screening and intrapartum prophylaxis for women who experience preterm labor or preterm premature rupture of membranes (pPROM)
- new recommended dosage of penicillin G for prophylaxis
- updated regimens for prophylaxis among women who are allergic to penicillin.

Who should receive prophylaxis?

In its report, the CDC reiterated the indications and “nonindications” for intrapartum prophylaxis (TABLE, page 22). Among the clarifications:

- Women who have GBS isolated from the urine at any time during pregnancy should undergo intrapartum prophylaxis. They do not need third-trimester screening for GBS.
- Women who had a previous infant with invasive GBS disease should also undergo intrapartum prophylaxis, with no need for third-trimester screening.

CONTINUED ON PAGE 22


When is intrapartum antibiotic prophylaxis indicated? When is it not?

<table>
<thead>
<tr>
<th>Indicated</th>
<th>Not indicated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previous infant with invasive GBS disease</td>
<td>Colonization with GBS during a previous pregnancy (unless an indication for GBS prophylaxis is present for current pregnancy)</td>
</tr>
<tr>
<td>GBS bacteriuria during any trimester of the current pregnancy*</td>
<td>GBS bacteriuria during previous pregnancy (unless an indication for GBS prophylaxis is present for current pregnancy)</td>
</tr>
<tr>
<td>Positive GBS vaginal-rectal screening culture in late gestation† during current pregnancy*</td>
<td>Negative vaginal and rectal GBS screening culture in late gestation† during the current pregnancy, regardless of intrapartum risk factors</td>
</tr>
<tr>
<td>Unknown GBS status at the onset of labor (culture not done, incomplete, or results unknown) and any of the following:</td>
<td>Cesarean delivery performed before onset of labor on a woman who has intact amniotic membranes, regardless of GBS colonization status or gestational age</td>
</tr>
<tr>
<td>• delivery at &lt;37 weeks’ gestation§</td>
<td></td>
</tr>
<tr>
<td>• amniotic membrane rupture ≥18 hours</td>
<td></td>
</tr>
<tr>
<td>• intrapartum temperature ≥100.4°F (≥38.0°C)†</td>
<td></td>
</tr>
<tr>
<td>• intrapartum nucleic acid amplification test positive for GBS**</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SOURCE: CDC²

¹ Intrapartum antibiotic prophylaxis is not indicated in this circumstance if a cesarean delivery is performed before onset of labor on a woman who has intact amniotic membranes.

² Optimal timing for prenatal GBS screening is at 35–37 weeks’ gestation.

³ Recommendations for the use of intrapartum antibiotics for prevention of early-onset GBS disease in the setting of threatened preterm delivery are presented in FIGURES 1 and 2.

⁴ If amnionitis is suspected, broad-spectrum antibiotic therapy that includes an agent known to be active against GBS should replace GBS prophylaxis.

⁵ NAAT testing for GBS is optional and might not be available in all settings. If intrapartum NAAT is negative for GBS but any other intrapartum risk factor (delivery at <37 weeks’ gestation, amniotic membrane rupture at ≥18 hours, or temperature ≥100.4°F [≥38.0°C]) is present, then intrapartum antibiotic prophylaxis is indicated.

FAST TRACK

When GBS prophylaxis is administered to a woman who has signs and symptoms of preterm labor, it should be discontinued if it is later determined that she is not in true labor.

• All other pregnant women should undergo screening at 35 to 37 weeks’ gestation. If results are positive, intrapartum prophylaxis is indicated.

CDC now offers distinct algorithms for preterm labor and pPROM

To clarify the management of two distinct groups of women, the CDC developed separate algorithms for GBS prophylaxis in the setting of threatened preterm delivery—one for spontaneous preterm labor (FIGURE 1, page 24) and another for pPROM (FIGURE 2, page 25). In addition, it now recommends:

• When GBS prophylaxis is given to a woman who has signs and symptoms of preterm labor, it should be discontinued if it is later determined that she is not in true labor

• If antibiotics given to prolong latency for pPROM include adequate coverage for GBS (i.e., 2 g intravenous [IV] ampicillin followed by 1 g IV ampicillin every 6 hours for 48 hours), no additional prophylaxis for GBS is necessary, provided delivery occurs during administration of that antibiotic regimen. Oral antibiotics alone are not adequate for GBS prophylaxis.

• When a woman who has pPROM is not in labor and is receiving antibiotics with adequate GBS coverage to prolong latency, she should be managed according to the standard of care for pPROM. GBS testing results should not affect the duration of antibiotics.

• When a woman who has pPROM is not in labor and is not receiving antibiotics to prolong latency (or is receiving antibiotics that do not have adequate GBS coverage), she should undergo GBS prophylaxis for 48 hours unless a GBS screen performed within 5 weeks was negative.

New dosage allows room for flexibility

The CDC now recommends a dosage of 5 million units of IV penicillin G for GBS prophylaxis, followed by 2.5 to 3.0 million units IV every 4 hours. The range of 2.5 to 3.0 million units is recommended to ensure that the
The CDC now recommends a dosage of 5 million units of IV penicillin G for GBS prophylaxis, followed by 2.5 to 3.0 million units IV every 4 hours.

Penicillin remains the agent of choice for intrapartum prophylaxis, but ampicillin is an acceptable alternative.

If a woman is allergic to penicillin but has no history of anaphylaxis, angioedema, respiratory distress, or urticaria following administration of a penicillin or cephalosporin, she should be given 2 g IV cefazolin, followed by 1 g IV cefazolin every 8 hours until delivery. If she does have a history of anaphylaxis or is at high risk for anaphylaxis, ask the laboratory for antimicrobial susceptibility testing on the antenatal GBS culture. If the isolate is susceptible to clindamycin, give her 900 mg IV clindamycin 8 hours until delivery. If it is not susceptible to clindamycin, give her 1 g IV vancomycin every 12 hours until the time of delivery.

The CDC no longer considers erythromycin to be an acceptable alternative for...
Penicillin remains the agent of choice for intrapartum prophylaxis, but ampicillin is an acceptable alternative.

**Where we go from here**

Although early-onset GBS disease has become relatively uncommon, the rate of maternal GBS colonization remains unchanged since the 1970s. Therefore, it is important to continue efforts to sustain and improve on the progress that has been made. There is also a need to monitor for potential adverse consequences of intrapartum antibiotic prophylaxis, such as emergence of bacterial antimicrobial resistance or an increased incidence or severity of non-GBS neonatal pathogens, the CDC observes. “In the absence of a licensed GBS vaccine, universal screening and intrapartum antibiotic prophylaxis continue to be the cornerstones of early-onset GBS disease prevention.”

**References**